Hanvon(SZ:002362)2026-01-30 11:25Financial Projections - The estimated net profit for 2025 is projected to be a loss of ¥22,000,000, compared to a loss of ¥18,000,000 in the previous year, and a loss of ¥11,015,950 in the same period last year[3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss of ¥22,900,000, compared to a loss of ¥18,900,000 in the previous year, and a loss of ¥12,191,360 in the same period last year[3]. - The basic earnings per share is expected to be -0.9000, compared to -0.7363 in the previous year, and -0.4506 in the same period last year[3]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[3]. Factors Affecting Profitability - The decline in net profit is attributed to increased competition in the domestic TOC market, leading to lower sales prices and higher raw material costs, resulting in decreased gross margins[5]. - Increased R&D expenses due to new product development and technology upgrades, including AI smart reading and AI electronic blood pressure monitors, which are still in the market expansion phase[5]. - The company has experienced a significant increase in foreign exchange losses due to a large proportion of foreign sales and holding certain dollar assets amidst a complex global economic situation[5]. - The company plans to make impairment provisions for certain assets based on the cautious principle, considering industry conditions and actual business situations[5]. Audit and Investor Guidance - The financial data in this earnings forecast has not been audited by the accounting firm, and there are no discrepancies between the company and the accounting firm regarding the earnings forecast[4]. - Investors are advised to make cautious decisions as the earnings forecast is based on preliminary estimates and the actual financial data will be disclosed in the 2025 annual report[6].